New drugs targeting tuberculosis using host defense mechanisms
Ubiquitin pathway modulators as novel antituberculosis drugs
This study is exploring new ways to help your body fight tuberculosis, especially the tougher strains that don't respond to regular treatments, by using a special protein called Parkin to boost your immune system and stop the bacteria from growing.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Progenra, INC. NIH-funded |
| Lab location | 1 site (Malvern, United States) |
| Project ID | NIH-11178166 on NIH RePORTER |
What this research studies
This research focuses on developing innovative drugs to treat tuberculosis (TB), particularly drug-resistant strains. It aims to utilize the body's own defense mechanisms, specifically targeting a protein called Parkin, which plays a crucial role in eliminating the bacteria that cause TB. By activating Parkin, the researchers hope to enhance the immune response against Mycobacterium tuberculosis, potentially leading to more effective treatments. The study will evaluate new compounds that can activate Parkin and assess their ability to inhibit TB growth in laboratory models.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals diagnosed with tuberculosis, especially those with drug-resistant forms of the disease.
Not a fit: Patients who do not have tuberculosis or those with other unrelated health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for both drug-sensitive and drug-resistant tuberculosis.
How similar studies have performed: Previous research has shown promise in using host defense mechanisms to combat infections, suggesting that this approach could be effective for tuberculosis as well.
Where this research is happening
Malvern, United States
- Progenra, INC. — Malvern, United States (Active)
Researchers
- Principal investigator: Suresh, Kumar — Progenra, INC.
- Study coordinator: Suresh, Kumar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.